Navigation Links
SOTIO a.s. Appoints Chiltern International
Date:3/18/2013

LONDON and Wilmington, N.C., March 18, 2013 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global contract research organization (CRO), announced that SOTIO a.s. has selected Chiltern International Limited to be the CRO that carries out the European part of its phase III global clinical trial entitled VIABLE, which will include 1,170 prostate cancer patients from Europe and the U.S.

Under the agreement signed in December 2012, Chiltern will be responsible for providing full-service management of the VIABLE phase III clinical trial in Europe. It will be the contracting party for 126 treatment centers in 17 European countries where a total of 750 patients are expected to participate in the trial. Chiltern will also be responsible for processing the data obtained during this clinical evaluation.

Dr Jim Esinhart , CEO, Chiltern, commented, "I am very pleased that we have been selected to manage this high profile trial. I believe it underscores the strengths and expertise of our global Oncology Therapeutic Area Team. We look forward to working in close partnership with Sotio to deliver a quality outcome."

Company profileAbout Chiltern: Established in 1982, Chiltern is a leading global clinical CRO with extensive experience in the management of Phase I-IV clinical trials across a broad range of therapeutic areas, functional service provision and contract staffing solutions. Chiltern has conducted trials in more than 40 countries, employs more than 1,500 people globally and offers services in Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Chiltern prides itself as a development partner that offers flexibility, responsiveness and quality delivery. Further information is available at: www.chiltern.com

About SOTIO a.s. Based in Czech Republic, SOTIO is a biotechnology company that is developing next generation Best-in-Class Active Cellular Immunotherapy ("ACI"), focusing on the treatment of cancer and autoimmune diseases. The company is in the process of developing new medical therapies using an immunotherapy platform based on activated dendritic cells with the view to significantly improving these treatments and making them available to patients. Further information is available at: www.sotio.comPlease contact:Natalie Chong, Marketing Director

Susan Ojanen, Marketing ExecutiveChiltern International Ltd. 

Chiltern International Inc.171 Bath Road 

1241 Volunteer Parkway, Suite 950Slough, Berkshire SL1 4AA, UK 

Bristol, TN 37620, USATel:  +44 (0) 1753 512 000 

Tel:  +1 (423) 968 9533natalie.chong@chiltern.com 

susan.ojanen@chiltern.com


'/>"/>
SOURCE Chiltern
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Arecor Appoints Dr. Sarah Howell as Chief Operating Officer
2. Elsevier / MEDai Appoints Tom Zajac as New President
3. Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer
4. Hybrid Fuels, Inc. Appoints Industry Expert as New CEO
5. BioStorage Technologies Appoints New Member to Board of Directors
6. Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development
7. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
8. PuraMed BioScience, Inc. Appoints Sue A. Baacke, CPA, as CFO
9. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
10. MAP Pharmaceuticals Appoints W. James OShea to Board of Directors
11. Veracyte Appoints Mark Spring as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016 - New FDA action date of ... FDA action date of July 22, 2016   ... 22, 2016   - Lifitegrast has ... indicated for the treatment of signs and symptoms of dry eye ... potential to be the only product approved in the U.S. in the past decade indicated ...
(Date:2/4/2016)... ... February 04, 2016 , ... Shimadzu Scientific Instruments will showcase ... demos and poster sessions, and present on the analysis of mycotoxins and medical ... 6 to 10 at the Georgia World Congress Center in Atlanta, Georgia. ...
(Date:2/4/2016)... 4, 2016 Beike Biotechnology, the ... attended a ceremony in late 2015 to mark their ... in 2016. --> --> ... for Personalized Cell Therapy" was hosted by the Shenzhen ... both subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... Columbia and MENLO PARK, Calif. ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused ... announced that it will present at the 18 th ... February 8, 2016 at 10:00 a.m. EST in ... , DelMar,s president and CEO, will provide an update on ...
Breaking Biology Technology:
(Date:2/3/2016)... --> --> Fourth quarter 2015:   ... with fourth quarter of 2014. Gross margin was 46% (32). ... Earnings per share increased to SEK 6.39 (loss: 0.49). ... --> --> January to ... up 1,142% compared with 2014. Gross margin was 43% (31). ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 ... of the bioinformatic market by reviewing the recent ... enabled tools that drive the field forward. Includes ... to: Identify the challenges and opportunities that ... providers and software solution developers, as well as ...
(Date:2/1/2016)... Rising sales of consumer electronics ... intuitive gesture control market size ... consumer electronics coupled with new technological advancements to drive ... through 2020   --> ... advancements to drive global touchfree intuitive gesture control market ...
Breaking Biology News(10 mins):